Whole exome sequencing of high-risk neuroblastoma identifies novel non-synonymous variants
暂无分享,去创建一个
L. Baumbusch | K. Beiske | S. Nygård | G. Trøen | S. Engebretsen | E. Ruud | Weronika Przybyła | Kirsti Marie Gjersvoll Paulsen | C. K. Mishra
[1] R. Schwarz,et al. Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions , 2021, Nature Communications.
[2] Yang Yu,et al. BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy , 2021, Translational oncology.
[3] Shailza Singh,et al. Structural genomics approach to investigate deleterious impact of nsSNPs in conserved telomere maintenance component 1 , 2021, Scientific Reports.
[4] G. Ljungman,et al. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance , 2020, Scientific Reports.
[5] S. Jang,et al. Genetic Alterations Detected by Targeted Next-generation Sequencing and Their Clinical Implications in Neuroblastoma , 2020, AntiCancer Research.
[6] Heather L. Mulder,et al. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations , 2020, Nature Communications.
[7] K. McHugh,et al. Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Y. Jamin,et al. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma , 2020, Journal of Experimental & Clinical Cancer Research.
[9] Annelisa M Cornel,et al. Monitoring Immune Responses in Neuroblastoma Patients during Therapy , 2020, Cancers.
[10] M. Gaze,et al. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1) , 2020, Cancers.
[11] G. Tonini,et al. Genetic predisposition and chromosome instability in neuroblastoma , 2020, Cancer and Metastasis Reviews.
[12] Guofeng Xu,et al. TRIM proteins in neuroblastoma , 2019, Bioscience reports.
[13] O. Delattre,et al. Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma , 2019, International journal of cancer.
[14] R. Palmer,et al. Targeting anaplastic lymphoma kinase in neuroblastoma , 2019, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[15] R. Pulido,et al. Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation , 2019, International journal of molecular sciences.
[16] T. Flægstad,et al. Clinically Relevant Biomarker Discovery in High-Risk Recurrent Neuroblastoma , 2019, Cancer informatics.
[17] M. Madonna,et al. Update on neuroblastoma. , 2019, Journal of pediatric surgery.
[18] J. Johnsen,et al. Neuroblastoma—A Neural Crest Derived Embryonal Malignancy , 2019, Front. Mol. Neurosci..
[19] F. Westermann,et al. A mechanistic classification of clinical phenotypes in neuroblastoma , 2018, Science.
[20] Zev A. Binder,et al. Genomic analysis identifies frequent deletions of Dystrophin in olfactory neuroblastoma , 2018, Nature Communications.
[21] Ruth Ladenstein,et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.
[22] G. Tonini,et al. Chromosome instability in neuroblastoma , 2018, Oncology letters.
[23] M. Macy,et al. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma , 2018, Drug design, development and therapy.
[24] D. Zwijnenburg,et al. RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma. , 2018, Cancer research.
[25] P. Lønning,et al. Patterns of genomic evolution in advanced melanoma , 2018, Nature Communications.
[26] K. Crandall,et al. Systematic pan-cancer analysis of somatic allele frequency , 2018, Scientific reports.
[27] Jinyan Li,et al. Delineation of the frequency and boundary of chromosomal copy number variations in paediatric neuroblastoma , 2018, Cell cycle.
[28] H. Seuánez,et al. Investigation of major genetic alterations in neuroblastoma , 2018, Molecular Biology Reports.
[29] Yan Shi,et al. Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo , 2017, Oncotarget.
[30] P. Ambros,et al. Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression , 2017, International journal of cancer.
[31] E. Barillot,et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries , 2017, Nature Genetics.
[32] Huanming Yang,et al. Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway. , 2017, Oncotarget.
[33] Eivind Hovig,et al. Personal Cancer Genome Reporter: variant interpretation report for precision oncology , 2017, bioRxiv.
[34] Günter Schreier,et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. , 2017, The Lancet. Oncology.
[35] P. Rocco,et al. OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes , 2017, Scientific Reports.
[36] Luca De Sano,et al. OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes , 2016, Scientific Reports.
[37] P. Raman,et al. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome , 2016, PLoS genetics.
[38] A. Nakagawara,et al. Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma , 2016, Journal of Hematology & Oncology.
[39] M. Loh,et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia , 2016, Proceedings of the National Academy of Sciences.
[40] Obi L. Griffith,et al. CIViC: A knowledgebase for expert-crowdsourcing the clinical interpretation of variants in cancer , 2016, bioRxiv.
[41] J. Mora,et al. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression , 2016, Oncotarget.
[42] Xu Zhou,et al. Genome-wide association study identifies multiple susceptibility loci for craniofacial microsomia , 2022 .
[43] D. Zwijnenburg,et al. Abstract PR06: TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors , 2016 .
[44] Gudrun Schleiermacher,et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations , 2015, Nature Genetics.
[45] Ravi Radhakrishnan,et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. , 2014, Cancer cell.
[46] Gaurav Kumar Pandey,et al. The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. , 2014, Cancer cell.
[47] G. E. Fernandez,et al. MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cell survival. , 2014, Cancer Research.
[48] F. Speleman,et al. Emergence of new ALK mutations at relapse of neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Scott J. Diede. Spontaneous regression of metastatic cancer: learning from neuroblastoma , 2014, Nature Reviews Cancer.
[50] B. Malnic,et al. Odorant receptor genes are expressed in olfactory neuroblastoma. , 2013, Genetics and molecular research : GMR.
[51] F. Gnad,et al. Assessment of computational methods for predicting the effects of missense mutations in human cancers , 2013, BMC Genomics.
[52] M. Harris,et al. Future of clinical genomics in pediatric oncology. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[54] Steven J. M. Jones,et al. The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.
[55] C. Printz. Advances in childhood cancers , 2012, Cancer.
[56] J. Khan,et al. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project , 2012, British Journal of Cancer.
[57] Li Ding,et al. The Pediatric Cancer Genome Project , 2012, Nature Genetics.
[58] Wendy S. W. Wong,et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..
[59] C. Sander,et al. Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.
[60] H. Hakonarson,et al. Genome-Wide Linkage Analysis to Identify Genetic Modifiers of ALK Mutation Penetrance in Familial Neuroblastoma , 2011, Human Heredity.
[61] M. Shah,et al. Targeting RET Receptor Tyrosine Kinase Activation in Cancer , 2010, Clinical Cancer Research.
[62] Helen X. Chen,et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.
[63] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[64] J. Maris. Recent advances in neuroblastoma. , 2010, The New England journal of medicine.
[65] N. Cheung,et al. Neuroblastoma: Therapeutic strategies for a clinical enigma. , 2010, Cancer treatment reviews.
[66] P. Kaatsch. Epidemiology of childhood cancer. , 2010, Cancer treatment reviews.
[67] Nunzio Iraci,et al. Molecular and Cellular Pathobiology Cancer Research p 53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma , 2010 .
[68] Matthew D. Young,et al. Gene ontology analysis for RNA-seq: accounting for selection bias , 2010, Genome Biology.
[69] A. Levine,et al. The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.
[70] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[71] Barbara Hero,et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] Giovanni Cecchetto,et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] Gudrun Schleiermacher,et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.
[74] W. Wang,et al. UTRN on chromosome 6q24 is mutated in multiple tumors , 2007, Oncogene.
[75] B. Hero,et al. Neuroblastoma , 2007, The Lancet.
[76] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[77] Miki Ohira,et al. LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. , 2005, Cancer research.
[78] A. Newton,et al. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.
[79] J. Trojanowski,et al. Association of ABCA2 expression with determinants of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[80] J. Lunec,et al. The p53 pathway and its inactivation in neuroblastoma. , 2003, Cancer letters.
[81] M. Tuchman,et al. Screening of infants and mortality due to neuroblastoma. , 2002, The New England journal of medicine.
[82] Hiroyuki Shimada,et al. Terminology and morphologic criteria of neuroblastic tumors , 1999, Cancer.
[83] X. Morin,et al. The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives , 1999, Nature.
[84] Marilyn M. Li,et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.
[85] Michael A. Hollingsworth,et al. Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.